CSIMarket Company Name, Ticker, Industry, else..


Mannkind Corporation  (NASDAQ: MNKD)
Other Ticker:  
 

Mannkind Corporation

MNKD's Fundamental analysis



Looking into Mannkind growth rates, revenue grew by 18.25 % in the first quarter of 2025 from the same quarter a year ago. Ranking at No. 564

Major Pharmaceutical Preparations industry recorded growth of revenues by 4.44 %

Mannkind's net income grew by 23.78 % in first quarter of 2025 year on year, above company average,

• More on MNKD's Growth


Mannkind
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Mannkind PEG ratio is at 0.22 Mannkind realized cash reduction of $ -0.45 per share in trailing twelve-month period.
Company
39.04
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.07.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.


• More on MNKD's Valuation
 
 Total Debt (Millions $) 36
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,473,243
 Net Income/Employee (TTM) $ 149,089
 Receivable Turnover (TTM) 14.48
 Tangible Book Value (Per Share $) -0.20

Mannkind
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Mannkind PEG ratio is at 0.22 Mannkind realized cash outflow of $ -0.45per share in trailing twelve-month period.
Company
39.04
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.07.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.


• More on MNKD's Valuation

•  Market Capitalization (Millions $) 1,210
•  Shares Outstanding (Millions) 321
•  Employees 202
•  Revenues (TTM) (Millions $) 298
•  Net Income (TTM) (Millions $) 30
•  Cash Flow (TTM) (Millions $) -145
•  Capital Exp. (TTM) (Millions $) -8
•  Total Debt (Millions $) 36
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 1,473,243
•  Net Income/Employee(TTM) $ 149,089
•  Receivable Turnover Ratio (TTM) 14.48
•  Tangible Book Value (Per Share $) -0.20

•  Market Capitalization (Millions $) 1,210
•  Shares Outstanding (Millions) 321
•  Employees 202
•  Revenues (TTM) (Millions $) 298
•  Net Income (TTM) (Millions $) 30
•  Cash Flow (TTM) (Millions $) -145
•  Capital Exp. (TTM) (Millions $) -8


    MNKD's Profitability Comparisons
Mannkind faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 28.45 % from 34.51 % in IV. Quarter.

Mannkind net profit margin of 16.79 % is currently ranking no. 33 in Major Pharmaceutical Preparations industry, ranking no. 69 in Healthcare sector and number 833 in S&P 500.


Profitability by Segment
Total 16.79 %



  Ratio
•   Capital Ratio (MRQ) 2.36
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) -
•  Asset Turnover Ratio (TTM) 0.69
•  Inventory Turnover Ratio (TTM) 2.15



Mannkind faced margin deterioration, primarily through cost pressure. Operating Margin fell in first quarter of 2025 to 28.45 % from 34.51 % in IV. Quarter.

Mannkind net profit margin of 16.79 % is currently ranking no. 33 in Major Pharmaceutical Preparations industry, ranking no. 69 in Healthcare sector and number 833 in S&P 500.

• More on MNKD's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com